Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea.
carcinoid syndrome
evidence-based medicine
neuroendocrine tumors
somatostatin analogs
telotristat ethyl
value-based care
Journal
P & T : a peer-reviewed journal for formulary management
ISSN: 1052-1372
Titre abrégé: P T
Pays: United States
ID NLM: 9015516
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
entrez:
2
7
2019
pubmed:
2
7
2019
medline:
2
7
2019
Statut:
ppublish
Résumé
Carcinoid syndrome causes substantial morbidity and reduces quality of life and survival. In a recent clinical trial, 97% of patients reported bowel movement-related issues, abdominal pain, flushing, and low energy. Combining somatostatin analogs with elotristat ethyl provides a new option for managing refractory CS symptoms. Health care providers should consider strategies that take advantage of approved dosing for patients with CS-related diarrhea.
Types de publication
Journal Article
Langues
eng
Pagination
424-427Déclaration de conflit d'intérêts
Disclosure: Editorial support was provided by Jeff Frimpter, MPH, funded by Lexicon Pharmaceuticals, Inc. The authors were not compensated in any form, directly or indirectly, relating to their authorship of this manuscript.
Références
Am J Gastroenterol. 1999 May;94(5):1381-7
pubmed: 10235222
Gastroenterol Nurs. 2002 May-Jun;25(3):105-11
pubmed: 12055378
J Surg Oncol. 2005 Mar 1;89(3):151-60
pubmed: 15719376
Pancreas. 2005 Nov;31(4):392-400
pubmed: 16258376
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Aliment Pharmacol Ther. 2009 Oct;30(7):733-40
pubmed: 19573169
CA Cancer J Clin. 2011 Mar-Apr;61(2):113-32
pubmed: 21388967
Cancer Res. 1990 Sep 15;50(18):5969-77
pubmed: 2168286
J Endocrinol Invest. 2012 Mar;35(3):326-31
pubmed: 21757992
Lancet. 2011 Dec 10;378(9808):2005-2012
pubmed: 22119496
Ann Oncol. 2012 Oct;23 Suppl 7:vii124-30
pubmed: 22997445
Gastrointest Cancer Res. 2012 Sep;5(5):161-8
pubmed: 23112884
Int J Hepatol. 2012;2012:973946
pubmed: 23227348
Med Devices (Auckl). 2012;5:103-9
pubmed: 23293542
Pancreas. 2013 May;42(4):557-77
pubmed: 23591432
N Engl J Med. 1986 Sep 11;315(11):663-6
pubmed: 2427948
Circulation. 1988 Feb;77(2):264-9
pubmed: 2448062
Oncologist. 2014 Sep;19(9):930-6
pubmed: 25096997
Cancer. 2015 Feb 15;121(4):589-97
pubmed: 25312765
Cancer Med. 2015 Jun;4(6):864-70
pubmed: 25727756
Neuroendocrinology. 2015;101(4):263-73
pubmed: 25871411
World J Gastroenterol. 2016 Feb 14;22(6):2118-25
pubmed: 26877616
J Clin Oncol. 2017 Jan;35(1):14-23
pubmed: 27918724
Ther Adv Med Oncol. 2017 Feb;9(2):127-137
pubmed: 28203303
Lancet Oncol. 2017 Apr;18(4):525-534
pubmed: 28238592
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
J Med Econ. 2017 Sep;20(9):945-951
pubmed: 28562131
Pancreas. 2017 Jul;46(6):707-714
pubmed: 28609356
Oncologist. 2017 Dec;22(12):1451-1462
pubmed: 28642335
J Glob Oncol. 2016 Jun 8;3(1):43-53
pubmed: 28717741
J Med Econ. 2018 Feb;21(2):182-188
pubmed: 28959913
J Exp Ther Oncol. 2017 Sep;11(2):91-96
pubmed: 28976130
Clin Ther. 2017 Nov;39(11):2158-2168
pubmed: 29074312
Clin Ther. 2017 Dec;39(12):2338-2344
pubmed: 29175096
Future Oncol. 2018 Oct;14(23):2361-2370
pubmed: 30095284
Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e490s
pubmed: 30133565
Oncologist. 2019 Feb;24(2):255-258
pubmed: 30171068
Circulation. 1993 Apr;87(4):1188-96
pubmed: 7681733
Eur J Cancer. 1998 Jul;34(8):1293-4
pubmed: 9849494